ReleaseWire Connect

Backed by factors, like strong promotional activities and aging population, the Japanese generics market will reach to the mark of US$ 10 Billion by 2013, says RNCOS.

With rise in income levels and government support, South African Banking Sector will surge at a CAGR of 10% during forecasted period, RNCOS identified.

RNCOS has recently launched “Ufida Software - Company Analysis” The study provides an overview on company’s history, business, its mergers and acquisitions, etc.

Treatment costs savings, patient compliance, drug safety & optimization of therapies will drive the growth of the global personalized medicines market, says RNCOS.

With rise in infrastructural development and comparatively low healthcare cost, Asian Medical Tourism market will surge at a CAGR of 17% during 2010-2012, RNCOS identified.

RNCOS has recently launched “Amgen Inc. - Company Analysis” The study provides an overview on company’s history, business, its mergers and acquisitions, etc. It covers profound information on the products and services offered by the company to make prospective clients aware about its product portfolio. It provides extensive financial information about the company to examine its financial health.

Russian insurance market will grow at a CAGR of around 12.3% during 2011-2014, says RNCOS in its latest research report.

With growing awareness, declining mobile tariffs, and availability of low cost handsets, the mobile subscriber base in rural India will surge at CAGR of around 35% during 2011-12 - 2013-14, RNCOS acknowledged.

According to our research report “China Insurance Sector Analysis”, China’s insurance industry is one of the fastest growing insurance industries in the world driven by rapid growth in both life insurance and general insurance products. The industry is at a brink of another high growth cycle with swift increase in awareness about benefits of getting insured, not only among individuals, but also among business fraternity. Insurance premiums in China are expected to grow at a CAGR of around 24% during 2011-2014.

India has become a prominent destination for the purpose of contract manufacturing of pharma products due to rising concerns over high production costs. Additionally, pharma giants are looking for convenient and faster transportation of products to the target markets. Besides, sponsor companies are looking to outsource related services, such as product development, packaging, and logistics. According to our latest research offering, “Indian Contract Manufacturing - A Hot Opportunity”, the contract manufacturing industry in is expected to grow at a magnificent CAGR of over 45% during 2011-2013. Growth will be much higher than the past years as the impacts of the global recession are wearing off from the market.